HGH Frag 176-191 Peptide Research
HGH Frag 176-191 is a growth-hormone fragment discussed for body-fat and lipolysis applications.
hgh fragment peptide
Preclinical
research maturity
Overview
HGH Frag 176-191 is a growth-hormone fragment discussed for body-fat and lipolysis applications. Its appeal comes from the idea that it may retain some fat-targeting biology of GH while avoiding the broader endocrine profile of full-length growth hormone.
Comparisons
Related stacks
Recomposition Stack
Metabolic Stack
Mechanism
The fragment is proposed to influence lipolysis and adipose metabolism without reproducing the full anabolic, glycemic, and IGF-1-mediated physiology of somatropin. That separation is central to its marketing appeal.
Clinical interest
Clinical interest focuses on fat loss, body recomposition, and metabolic optimization. It sits conceptually between traditional GH fragments and modern obesity pharmacology, but without the evidentiary depth of approved incretin drugs.
Research summary
The literature includes obesity-model work and reviews on GH fragments in obesity pharmacotherapy. Compared with semaglutide, tirzepatide, or even tesamorelin, the evidence base is far thinner and not practice-defining.
Safety considerations
Long-term human safety, formulation quality, and real-world effect size remain uncertain. The biggest communication risk is implying equivalence to approved obesity therapies or to full GH replacement.
Key information
Research stage
Preclinical
Evidence rating
Low
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
5
)
Frequently asked questions
What is HGH Frag 176-191?
It is a synthetic fragment of human growth hormone studied for lipolytic and anti-obesity effects without the full endocrine profile of native GH.
Is HGH Frag 176-191 the same as growth hormone?
No. Somatropin is full recombinant human GH, while HGH Frag 176-191 is only a fragment intended to isolate certain fat-related effects.